Advent Access has secured S$2.6m ($1.92m) in a pre-series A venture financing round led by Accuron MedTech.
The Singapore-based company plans to use the funds to progress the development of its av-Guardian technology, which provides vascular access to dialysis patients.
Linear Health Sciences LLC has secured additional funding of $1.54m in a series A venture financing round, bringing the total funds raised to $3m.
The company previously raised $1.2m from i2E, SeedStep Angels Group, and other investors.
The US-based safety technology solutions firm plans to use the proceeds for developing orchid safety release valve (SRV).
US-based medical devices developer Virtual Incision Corporation has secured $18m in a series B financing round led by Bluestem Capital Company LLC and Sinopharm Capital Management Co Ltd.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Virtual Incision plans to use the proceeds to submit a pre-market notification to the US Food and Drug Administration (FDA) for its miniaturised robotically assisted surgical device (RASD).
Skyline Medical Inc plans to raise $2.29m through a public offering of 1,857,179 shares of its common stock priced at $1.24 a share.
Esousa holdings LLC will issue the shares as the selling stockholder from time to time.
Brazilian diagnostic services provider Fleury SA has raised $92m through a public offering of notes.
Banco Itau BBA SA served as the underwriter for the offering.
Orthocell Ltd has raised A$1.5m ($1.13m) through the private placement of 4,411,765 shares priced at A$0.34 ($0.25) each.
The regenerative medicine company plans to use the funds towards research activities and for the commercialisation of its pipeline products, including CelGro and Ortho – ATI.